50 Northern Avenue
23 articles with Entrada Therapeutics
Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointments of Nerissa Kreher, M.D., as Chief Medical Officer and Kory Wentworth as Chief Financial Officer. Dr. Kreher, a physician executive with a 15-year record o
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.